Treating the Liver: Your Cholesterol Command Center

Cardiovascular disease remains one of our most urgent health challenges, claiming roughly 3.2 million lives across India each year—accounting for nearly one in four deaths. In my daily practice at Ashok One Hospital, I frequently discuss the primary modifiable driver behind this: elevated low-density lipoprotein (LDL), commonly known as "bad cholesterol".

When LDL cholesterol circulates in excess, it deposits along arterial walls, forming rigid plaques that restrict blood flow to the heart and brain. Understanding how our bodies process cholesterol—and the remarkable ways modern medicine can now target it—is vital to protecting your long-term heart health.

The Liver: Your Cholesterol Command Center

Your liver plays a dual role: it synthesizes the cholesterol needed to construct cellular walls, but it also acts as a primary filter. Specialized receptors on the liver’s surface capture circulating LDL particles from your blood and draw them inside to be safely recycled or excreted in bile. That is the main reason why diet alone is not enough

For over thirty years, statins have served as the foundation of cholesterol management. Statins work by inhibiting the specific enzyme the liver uses to produce cholesterol. When production slows, the liver pulls more LDL from the bloodstream, reducing heart attacks and strokes. However, statins have a ceiling—even maximum doses typically lower LDL by 35% to 40%. For patients at very high cardiovascular risk or those with genetic conditions, we often need deeper reductions.

The New Era: Targeting PCSK9

In recent years, lipid management has advanced by targeting a protein called PCSK9. Normally, PCSK9 attaches to LDL receptors and destroys them, leaving fewer receptors available to clear cholesterol from your blood. By blocking PCSK9, we allow receptors to survive longer and clear far more LDL.

We now have multiple distinct approaches targeting this pathway:

• Monoclonal Antibodies (Evolocumab & Alirocumab): Injected subcutaneously every two weeks, these antibodies neutralize PCSK9 directly, reducing LDL levels by an additional 50% to 60% beyond statin therapy.

• Small Interfering RNA (Inclisiran): Rather than neutralizing existing PCSK9, inclisiran prevents the liver from producing the protein in the first place. Administered as just two injections per year, it cuts LDL levels by approximately 50%.

• Oral PCSK9 Inhibitors (Enlicitide): Developed as a once-daily tablet engineered to survive digestive breakdown, this pill delivers roughly 56% LDL reduction without injections.

Looking Ahead: Permanent Gene Editing

On the cutting edge, experimental gene therapies like VERVE-102 and CTX310 are currently undergoing early human clinical trials. Using a single infusion, these therapies aim to permanently edit liver cell DNA—switching off the genes responsible for PCSK9 or ANGPTL3 so cholesterol remains low without ongoing treatment.

Finding Your Target

Cholesterol targets are not one-size-fits-all. For high-risk individuals or those who have experienced a prior cardiac event or stroke, our target LDL level is often below 50 mg/dL, and sometimes below 30 mg/dL. If you are struggling to reach your targets on traditional statins alone, schedule a visit so we can tailor a treatment plan that keeps your heart protected.